Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy
Sponsored by Centre Hospitalier Universitaire de Saint Etienne
About this trial
Last updated 8 years ago
Study ID
1108060
Status
Completed
Type
Interventional
Phase
N/A
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 11 years ago
What is this trial about?
The anti-hinge region antibodies would be a relevant biomarker of IgA nephropathy. Beyond
a prognostic value (which could increase the risk of Renal Absolute), the longitudinal
monitoring for these antibodies could be of interest: (1) in the monitoring of patients
(in place including a possible repetition renal biopsy); (2) to guide treatment decisions
and (3) in clinical research, as an outcome (in substitution for the occurrence of kidney
failure) in therapeutic trials IgA nephropathy.
This research project constitutes the first step in validating these antibodies biomarker
of IgA nephropathy and its main objective is to study the performance of the blood levels
of anti-hinge region antibodies in the diagnosis of progressive forms of histologically
IgA nephropathy as defined by the Renal Risk Absolute.
The secondary objectives of this project are to establish a bio-collection that will
allow us to search for other prognostic factors (genetic, cellular and serum) of IgA
nephropathy and to evaluate the performance of Renal Absolute risk by integrating Oxford
score, the new international histological classification.
What are the participation requirements?
Inclusion Criteria
- Major Patient
- Diagnosis of a primitive form of IgA nephropathy histologically proven
Exclusion Criteria
- Suspicion of secondary IgA nephropathy forms
- Less than 5 glomeruli present on renal biopsy